Is it the heart or the mind—and which psychotropic is safe to prescribe? This update reviews QTc risk, orthostasis, and metabolic effects across antidepressants and antipsychotics in cardiac patients.

Antipsychotics can worsen motor symptoms and raise mortality in Parkinson's disease psychosis, leaving clinicians with few good options. Could an industry-funded expert panel's new algorithm change practice for these patients?

Patients on antipsychotics often assume sedation will fade as tolerance develops—but does it, and how quickly? A large pooled analysis tracks the sedation timeline across medications, revealing notable differences by agent.

David Osser, MD, explains why treating sleep first is central to PTSD care—and how to use prazosin effectively despite lingering controversies.

A new placebo-controlled trial suggests lumateperone rapidly improves depressive and manic symptoms in mixed features—with minimal metabolic or EPS burden.

An evidence-based approach using metformin offers clinicians a proactive strategy to protect metabolic health.

When first-line treatments fail, should clozapine be considered for severe aggression in autistic youth? A retrospective chart review suggests reduced hospital visits and meaningful clinical improvement in carefully monitored patients. We review who might benefit—and how to balance efficacy with safety and monitoring demands.

Steroid-induced mania doesn’t just happen in bipolar disorder. This review tells us how common it is in the general population and when to expect it. 

Do antipsychotics raise breast cancer risk? A new study suggests that long-term use of prolactin-raising antipsychotics may increase that risk in women with severe mental illness. We review the findings, highlight which medications pose greater concern, and offer guidance on monitoring, screening, and prescribing safer alternatives when appropriate.